Oncology Care Model Reduces Cost of Supportive Care Meds Oncology Care Model Reduces Cost of Supportive Care Meds
The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim). The FDA approval was based on a review of data that demonstrated a high degree of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 29, 2021 Category: Biotechnology Authors: Laura Newpoff Source Type: news

Experts discuss the importance of successful adoption of biosimilars in the US health care system
Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 29, 2021 Category: American Health Authors: Laura Newpoff Source Type: news

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Nivestym (Filgrastim-aafi Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 20, 2021 Category: Drugs & Pharmacology Source Type: news

filgrastim (Neupogen)
Title: filgrastim (Neupogen)Category: MedicationsCreated: 9/19/2000 12:00:00 AMLast Editorial Review: 8/2/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 2, 2019 Category: Cancer & Oncology Source Type: news

Savings With Biosimilar Filgrastim Unclear Savings With Biosimilar Filgrastim Unclear
Projected cost savings from switching to biosimilar filgrastim from the reference drug depend on the data analyzed.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Amgen Donates $93 Million Worth of Cancer Medicines THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab). Patients will access the donated medicines through Direct Relief-partner hospitals and clinics in the following countries: Armenia, Ca...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Early Insights into Biosimilar Cost Savings in the United States
A recent study inJAMA Oncologyexamined the average daily cost of  biosimilar filgrastim-sndz compared with the brand name biologic. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Teva Announces Updated Indication and Vial Presentation for Granix (tbo-filgrastim) Injection in United States
JERUSALEM--(BUSINESS WIRE)--Aug. 6, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim) Injection for a new vial presentation and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 6, 2018 Category: Drugs & Pharmacology Source Type: news

Nivestym (Filgrastim-aafi Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 6, 2018 Category: Drugs & Pharmacology Source Type: news

Second Filgrastim Biosimilar Gets Thumbs Up From the FDA Second Filgrastim Biosimilar Gets Thumbs Up From the FDA
The FDA has granted approval to Nivestym, which has several clinical uses.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 20, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

Neupogen (Filgrastim Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 11, 2018 Category: Drugs & Pharmacology Source Type: news